NEW YORK (GenomeWeb News) – Metabolon has reeled in $6 million in new Series C financing from new investors Syngenta Ventures and Fletcher Spaght Ventures, and from previous investors, bringing the total funding for the round to $12.3 million, the company said today.

The Research triangle Park, NC-based metabolomic diagnostics company also said that it has agreed to expand an earlier research collaboration with Syngenta, and that Syngenta Ventures VP Carol Marina and Fletcher Spaght VP Guy Fish have joined its board of directors.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: factors influencing retrotransposon integration sites, and more.

A bioethicist argues for the responsible use of germline gene editing.

Some breweries are using DNA-based testing to determine whether unwanted bacteria are affecting their beers, The Verge reports.

Standardized N-of-1 trials will be needed to test out personalized medicines, writes Nicholas Schork from the J. Craig Venter Institute at Nature.